6-aminobenzyl-3-methyl-5-nitropyridine | 867012-62-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-aminobenzyl-3-methyl-5-nitropyridine
• 英文别名: N-benzyl-3-methyl-5-nitropyridin-2-amine
• CAS: 867012-62-2
• 化学式: C₁₃H₁₃N₃O₂
• 分子量: 243.265
• InChiKey: BKFREPONSPMWBL-UHFFFAOYSA-N

物化性质

• 沸点：
  418.5±45.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  70.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-aminobenzyl-3-methyl-5-nitropyridine 在 palladium 10% on activated carbon 、 三氟化硼乙醚 、 ammonium acetate 、 sodium sulfate 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Design, synthesis and structure–activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors

  摘要：

  This Letter describes the discovery and SAR optimization of 1,5-tetrahydronaphthyridines, a new class of potent CETP inhibitors. The effort led to the identification of 21b and 21d with in vitro human plasma CETP inhibitory activity in the nanomolar range (IC50 = 23 and 22 nM, respectively). Both 21b and 21d exhibited robust HDL-c increase in hCETP/hApoA1 dual heterozygous mice model. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.075
• 作为产物：
  描述：

  2-氯-3-甲基-5-硝基吡啶 、 苄胺 在 palladium diacetate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 生成 6-aminobenzyl-3-methyl-5-nitropyridine
  参考文献：
  名称：

  Design, synthesis and structure–activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors

  摘要：

  This Letter describes the discovery and SAR optimization of 1,5-tetrahydronaphthyridines, a new class of potent CETP inhibitors. The effort led to the identification of 21b and 21d with in vitro human plasma CETP inhibitory activity in the nanomolar range (IC50 = 23 and 22 nM, respectively). Both 21b and 21d exhibited robust HDL-c increase in hCETP/hApoA1 dual heterozygous mice model. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.075

文献信息

• Compounds and methods for treating dyslipidemia
  申请人：Bell Gregory Michael

  公开号：US20070173526A1

  公开（公告）日：2007-07-26

  The present invention discloses compounds of formula (I) wherein A, n, q, K, W, X, Y; Z, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and its sequelae.

  本发明披露了化合物的公式（I），其中A，n，q，K，W，X，Y; Z，R1，R2，R3，R4，R5和R6如本文所定义，并披露了它们的药物组成物和使用方法，用于治疗脂质代谢紊乱及其后遗症。
• COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA
  申请人：ELI LILLY AND COMPANY

  公开号：EP1735320A1

  公开（公告）日：2006-12-27
• US7470705B2
  申请人：——

  公开号：US7470705B2

  公开（公告）日：2008-12-30
• [EN] COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA<br/>[FR] COMPOSES ET PROCEDES PERMETTANT DE TRAITER LA DYSLIPIDEMIE
  申请人：LILLY CO ELI

  公开号：WO2005097806A1

  公开（公告）日：2005-10-20

  The present invention discloses compounds of formula (I) wherein A, n, q, K, W, X, Y, Z, R1, R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and its sequelae.
• Design, synthesis and structure–activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors
  作者：Maria-Carmen Fernandez、Ana Escribano、Ana I. Mateo、Saravanan Parthasarathy、Eva M. Martin de la Nava、Xiaodong Wang、Sandra L. Cockerham、Thomas P. Beyer、Robert J. Schmidt、Guoqing Cao、Youyan Zhang、Timothy M. Jones、Anthony Borel、Stephanie A. Sweetana、Ellen A. Cannady、Gregory Stephenson、Scott Frank、Nathan B. Mantlo

  DOI：10.1016/j.bmcl.2012.03.075

  日期：2012.5

  This Letter describes the discovery and SAR optimization of 1,5-tetrahydronaphthyridines, a new class of potent CETP inhibitors. The effort led to the identification of 21b and 21d with in vitro human plasma CETP inhibitory activity in the nanomolar range (IC50 = 23 and 22 nM, respectively). Both 21b and 21d exhibited robust HDL-c increase in hCETP/hApoA1 dual heterozygous mice model. (C) 2012 Elsevier Ltd. All rights reserved.